PIM1

Serine/threonine-protein kinase pim-1

303,904 patent compounds predicted against PIM1, 172,970 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL102044	1.00	20/20
SCHEMBL102126	1.00	20/20
SCHEMBL102129	1.00	20/20
SCHEMBL102159	1.00	20/20
SCHEMBL102171	1.00	20/20
SCHEMBL102183	1.00	20/20
SCHEMBL102215	1.00	20/20
SCHEMBL102224	1.00	20/20
SCHEMBL102397	1.00	20/20
SCHEMBL102398	1.00	20/20
SCHEMBL102411	1.00	20/20
SCHEMBL102495	1.00	20/20
SCHEMBL102496	1.00	20/20
SCHEMBL102538	1.00	20/20
SCHEMBL102539	1.00	20/20
SCHEMBL102542	1.00	20/20
SCHEMBL102544	1.00	20/20
SCHEMBL102556	1.00	20/20
SCHEMBL102561	1.00	20/20
SCHEMBL102682	1.00	20/20

Germline variants in PIM1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full PIM1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to PIM1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab	PHASE4	UNKNOWN
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy	PHASE3	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer	PHASE2	UNKNOWN
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer	PHASE2	RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma	PHASE2	UNKNOWN
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer	PHASE2	UNKNOWN
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer	PHASE2	NOT_YET_RECRUITING
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1	PHASE2	COMPLETED
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias	PHASE1	WITHDRAWN
A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects	PHASE1	COMPLETED
A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects	PHASE1	COMPLETED
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer	PHASE1	UNKNOWN
Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis	PHASE1	COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects	PHASE1	COMPLETED
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy	PHASE1	UNKNOWN
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)	PHASE1	COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function	PHASE1	COMPLETED
Evaluation of Hypoxia in Primary Melanoma	nan	RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PIM1 binder may also engage these)

Protein	Name	Similarity
Q95LJ0	—	1.000	Q95LJ0 →
P26794	—	1.000	P26794 →
P06803	—	1.000	P06803 →
Q9N0P9	—	0.997	Q9N0P9 →
Q9PU85	—	0.993	Q9PU85 →
Q91822	—	0.986	Q91822 →
Q9YHZ5	—	0.981	Q9YHZ5 →
P58750	—	0.980	P58750 →
O70444	—	0.980	O70444 →
TSSK1B	Testis-specific serine/threonine-protein kinase 1	0.978	landscape →
Q5RCY1	—	0.974	Q5RCY1 →
Q8C1R0	—	0.974	Q8C1R0 →
Q63285	—	0.973	Q63285 →
Q62070	—	0.972	Q62070 →
Q9R011	—	0.971	Q9R011 →
PIM3	Serine/threonine-protein kinase pim-3	0.971	landscape →
TSSK2	Testis-specific serine/threonine-protein kinase 2	0.970	landscape →
Q91VB2	—	0.969	Q91VB2 →
Q8BG48	—	0.969	Q8BG48 →
A0JM20	—	0.969	A0JM20 →
Q61288	—	0.969	Q61288 →
Q9YI66	—	0.969	Q9YI66 →
P70218	—	0.969	P70218 →
Q9QYZ6	—	0.968	Q9QYZ6 →
Q8K4T3	—	0.968	Q8K4T3 →
Q4R6L3	—	0.968	Q4R6L3 →
A6H751	—	0.967	A6H751 →
Q9QZ05	—	0.967	Q9QZ05 →
D3ZHP7	—	0.966	D3ZHP7 →
Q91XS8	—	0.966	Q91XS8 →